Lab
Florida Clinical Practice Association INC
Florida Clinical Practice Association INC was paid $3.13M by Medicaid between Jan 2018 and Dec 2024, across 86 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 52% of everything it billed.
33Billing provider infoFLORIDA CLINICAL PRACTICE ASSOCIATION INC
GAINESVILLE, FL 32608
GAINESVILLE, FL 32608
33aNPI1326108903assigned 12/12/2006
33bProvider typeClinical Medical Laboratory
28Total paid$3.13M
24GClaims148,725
24DCodes billed86
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Florida
Rank by total paid#21 of 225
Median peer was paid$74K
This provider vs. median43×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 962 | $6K | |
| 2019 | 5,863 | $79K | |
| 2020 | 14,286 | $486K | |
| 2021 | 40,321 | $1.35M | |
| 2022 | 38,040 | $747K | |
| 2023 | 33,462 | $357K | |
| 2024incomplete | 15,791 | $106K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 52% | 26,618 | 24,090 | $1.63M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 14% | 10,907 | 9,662 | $426K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 5.4% | 6,599 | 5,599 | $169K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 4.0% | 4,449 | 4,230 | $126K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.9% | 4,628 | 4,386 | $92K |
| 88142 | 1.9% | 4,429 | 4,280 | $58K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 6,044 | 5,419 | $51K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 2,502 | 2,272 | $49K |
| 81513 | 1.3% | 469 | 436 | $40K | |
| 80053 | Comprehensive metabolic panel | 1.1% | 9,448 | 8,276 | $35K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 9,024 | 7,997 | $34K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,737 | 2,257 | $30K |
74 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,100 | $29K |
| 86317 | <1% | 961 | $27K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,671 | $25K |
| 86803 | <1% | 3,000 | $25K | |
| 80061 | Lipid panel | <1% | 5,698 | $23K |
| 87522 | Neg quan hep c or qual rna | <1% | 746 | $20K |
| 87631 | <1% | 209 | $20K | |
| 82607 | <1% | 2,979 | $20K | |
| 87340 | <1% | 2,482 | $14K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 930 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,016 | $13K |
| 82728 | <1% | 2,181 | $13K | |
| 88342 | <1% | 297 | $12K | |
| 88341 | <1% | 97 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 818 | $11K |
| 83655 | <1% | 1,218 | $10K | |
| 85027 | <1% | 3,434 | $10K | |
| 86762 | <1% | 904 | $8K | |
| 87081 | <1% | 1,845 | $8K | |
| 87186 | <1% | 1,636 | $7K | |
| 84439 | <1% | 2,289 | $7K | |
| 99499 | <1% | 54 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 84 | $5K |
| 87481 | <1% | 440 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,151 | $5K |
| 83550 | <1% | 1,365 | $4K | |
| 88291 | <1% | 169 | $4K | |
| 82570 | <1% | 1,690 | $3K | |
| 83540 | <1% | 1,471 | $3K | |
| 87529 | <1% | 55 | $2K | |
| 86787 | <1% | 484 | $2K | |
| 82746 | <1% | 422 | $2K | |
| 81001 | <1% | 1,730 | $2K | |
| 84480 | <1% | 394 | $2K | |
| 88312 | <1% | 47 | $2K | |
| 86850 | <1% | 761 | $2K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 122 | $1K |
| 81225 | <1% | 15 | $1K | |
| 88304 | <1% | 105 | $1K | |
| 86140 | <1% | 484 | $1K | |
| 86900 | <1% | 826 | $1K | |
| 82950 | <1% | 436 | $1K | |
| 87563 | <1% | 40 | $970.87 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 18 | $956.32 |
| 84403 | <1% | 69 | $873.81 | |
| 87625 | <1% | 67 | $865.05 | |
| 86480 | <1% | 27 | $736.22 | |
| 87070 | <1% | 163 | $735.78 | |
| 86901 | <1% | 802 | $735.19 | |
| 86235 | <1% | 32 | $694.74 | |
| 82670 | <1% | 32 | $517.20 | |
| 85652 | <1% | 362 | $468.12 | |
| 86141 | <1% | 33 | $434.26 | |
| 83735 | <1% | 171 | $431.66 | |
| 84402 | <1% | 22 | $321.31 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 54 | $311.01 |
| 82136 | <1% | 52 | $274.77 | |
| 83970 | <1% | 14 | $237.73 | |
| 85610 | <1% | 93 | $228.37 | |
| 86376 | <1% | 27 | $216.81 | |
| 80076 | <1% | 31 | $176.84 | |
| 87536 | <1% | 17 | $172.58 | |
| 82105 | <1% | 12 | $143.08 | |
| 84156 | <1% | 168 | $141.35 | |
| 83001 | <1% | 16 | $126.39 | |
| 84153 | <1% | 24 | $124.92 | |
| 81003 | <1% | 97 | $73.85 | |
| 84270 | <1% | 14 | $69.78 | |
| 82550 | <1% | 31 | $59.23 | |
| 87184 | <1% | 12 | $56.30 | |
| 82248 | <1% | 90 | $49.63 | |
| 84550 | <1% | 13 | $20.38 | |
| 82043 | <1% | 409 | $8.77 | |
| G0452 | Molecular pathology procedure; physician interpretation and report | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIBISKI, JEREMY (EXECUTIVE DIR OF FINANCE AND ADMIN)
| Provider | Location | Paid |
|---|---|---|
| Florida Clinical Practice Association INC | Gainesville, FL | $79.31M |
| Florida Clinical Practice Association INC | Gainesville, FL | $132K |
| Florida Clinical Practice Association INC | Gainesville, FL | $28K |
| Florida Clinical Practice Association INC | Gainesville, FL | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.